|
| 36288512 | Alliance A071401: Phase II Trial of Focal Adhesion Kinase Inhibition in Meningiomas With Somatic <i>NF2</i> Mutations. | J Clin Oncol | 2023 |
| 37722087 | Inaugural Results of the Individualized Screening Trial of Innovative Glioblastoma Therapy: A Phase II Platform Trial for Newly Diagnosed Glioblastoma Using Bayesian Adaptive Randomization. | J Clin Oncol | 2023 |
| 37188783 | Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial. | Nat Med | 2023 |
| 37317993 | Preclinical and clinical evaluation of Buparlisib (BKM120) in recurrent/refractory Central Nervous System Lymphoma. | Leuk Lymphoma | 2023 |
| 36634606 | NCCN Guidelines® Insights: Central Nervous System Cancers, Version 2.2022. | J Natl Compr Canc Netw | 2023 |
| 34801160 | Biology and Treatment of Meningiomas: A Reappraisal. | Hematol Oncol Clin North Am | 2022 |
| 35440655 | Brain radiotherapy, tremelimumab-mediated CTLA-4-directed blockade +/- trastuzumab in patients with breast cancer brain metastases. | NPJ Breast Cancer | 2022 |
| 35395080 | Circulating Immune Cell and Outcome Analysis from the Phase II Study of PD-L1 Blockade with Durvalumab for Newly Diagnosed and Recurrent Glioblastoma. | Clin Cancer Res | 2022 |
| 35940825 | Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors. | J Immunother Cancer | 2022 |
| 35908833 | EANO - EURACAN - SNO Guidelines on circumscribed astrocytic gliomas, glioneuronal, and neuronal tumors. | Neuro Oncol | 2022 |
| 35948444 | Combination Olaparib and Temozolomide for the Treatment of Glioma: A Retrospective Case Series. | Neurology | 2022 |
| 33199490 | Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma. | Clin Cancer Res | 2021 |
| 33582005 | Leptomeningeal disease in pancreas ductal adenocarcinoma: A manifestation of longevity. | Pancreatology | 2021 |
| 32293798 | Phase I clinical trial of temsirolimus and perifosine for recurrent glioblastoma. | Ann Clin Transl Neurol | 2020 |
| 31873875 | DCE-MRI perfusion predicts pseudoprogression in metastatic melanoma treated with immunotherapy. | J Neurooncol | 2020 |
| 33152700 | Challenges in the Treatment of Newly Diagnosed and Recurrent Primary Central Nervous System Lymphoma. | J Natl Compr Canc Netw | 2020 |
| 33152694 | Central Nervous System Cancers, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. | J Natl Compr Canc Netw | 2020 |
| 32642703 | Value of [<sup>18</sup>F]-FDG positron emission tomography in patients with recurrent glioblastoma receiving bevacizumab. | Neurooncol Adv | 2020 |
| 30643254 | Tumor mutational load predicts survival after immunotherapy across multiple cancer types. | Nat Genet | 2019 |
| 30137421 | Proposed response assessment and endpoints for meningioma clinical trials: report from the Response Assessment in Neuro-Oncology Working Group. | Neuro Oncol | 2019 |
| 31325145 | Phase II trial of an AKT inhibitor (perifosine) for recurrent glioblastoma. | J Neurooncol | 2019 |
| 31263031 | Genomic Correlates of Disease Progression and Treatment Response in Prospectively Characterized Gliomas. | Clin Cancer Res | 2019 |
| 31432377 | Evaluation of toxicity of carmustine with or without bevacizumab in patients with recurrent or progressive high grade gliomas. | J Neurooncol | 2019 |
| 30742122 | Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. | Nat Med | 2019 |
| 31117044 | Management of Central Nervous System Tumors. | J Natl Compr Canc Netw | 2019 |
| 30567753 | Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma. | Blood | 2019 |
| 29559563 | Phase I Study of MEDI3617, a Selective Angiopoietin-2 Inhibitor Alone and Combined with Carboplatin/Paclitaxel, Paclitaxel, or Bevacizumab for Advanced Solid Tumors. | Clin Cancer Res | 2018 |
| 30221993 | Rapid infusion rituximab is well tolerated in patients with primary CNS lymphoma. | CNS Oncol | 2018 |
| 31218270 | Genomic Heterogeneity Underlies Mixed Response to Tropomyosin Receptor Kinase Inhibition in Recurrent Glioma. | JCO Precis Oncol | 2018 |
| 30351999 | BRAF Inhibition in <i>BRAF</i><sup>V600</sup>-Mutant Gliomas: Results From the VE-BASKET Study. | J Clin Oncol | 2018 |
| 29388793 | Radiographic patterns of recurrence and pathologic correlation in malignant gliomas treated with bevacizumab. | CNS Oncol | 2018 |
| 29683790 | Multicenter Phase IB Trial of Carboxyamidotriazole Orotate and Temozolomide for Recurrent and Newly Diagnosed Glioblastoma and Other Anaplastic Gliomas. | J Clin Oncol | 2018 |
| 28890946 | OncoKB: A Precision Oncology Knowledge Base. | JCO Precis Oncol | 2017 |
| 31044081 | Bevacizumab in high-grade glioma patients following intraparenchymal hemorrhage. | Neurooncol Pract | 2017 |
| 28472509 | Multicenter phase II study of temozolomide and myeloablative chemotherapy with autologous stem cell transplant for newly diagnosed anaplastic oligodendroglioma. | Neuro Oncol | 2017 |
| 29118226 | NCCN Guidelines Insights: Central Nervous System Cancers, Version 1.2017. | J Natl Compr Canc Netw | 2017 |
| 28619981 | Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma. | Cancer Discov | 2017 |
| 28870792 | Multicenter, Phase 1, Dose Escalation Study of Hypofractionated Stereotactic Radiation Therapy With Bevacizumab for Recurrent Glioblastoma and Anaplastic Astrocytoma. | Int J Radiat Oncol Biol Phys | 2017 |
| 26691210 | Integration of 2-hydroxyglutarate-proton magnetic resonance spectroscopy into clinical practice for disease monitoring in isocitrate dehydrogenase-mutant glioma. | Neuro Oncol | 2016 |
| 26538618 | Large-volume low apparent diffusion coefficient lesions predict poor survival in bevacizumab-treated glioblastoma patients. | Neuro Oncol | 2016 |
| 27826680 | Phase I study of RO4929097 with bevacizumab in patients with recurrent malignant glioma. | J Neurooncol | 2016 |
| 27154916 | Molecular and Clinical Effects of Notch Inhibition in Glioma Patients: A Phase 0/I Trial. | Clin Cancer Res | 2016 |
| 25100872 | Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma. | Neuro Oncol | 2015 |
| 26275367 | Dynamic contrast enhanced T1 MRI perfusion differentiates pseudoprogression from recurrent glioblastoma. | J Neurooncol | 2015 |
| 26483059 | Central Nervous System Cancers, Version 1.2015. | J Natl Compr Canc Netw | 2015 |
| 26338913 | T1-Weighted Dynamic Contrast-Enhanced MRI as a Noninvasive Biomarker of Epidermal Growth Factor Receptor vIII Status. | AJNR Am J Neuroradiol | 2015 |
| 25837903 | Benign brain tumors and tumors associated with phakomatoses. | Continuum (Minneap Minn) | 2015 |
| 25910950 | A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients. | Clin Cancer Res | 2015 |
| 26008604 | A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma. | Neuro Oncol | 2015 |
| 25527270 | Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma. | Neurology | 2015 |